Evidence map›Paper›PMID 39219429›Full record

ReviewMini reviews in medicinal chemistry2025

Cinnamic Acid Derivatives: Recent Discoveries and Development Strategies for Alzheimer's Disease.

Yuan Liu, Zhixian Zhang, Zeyu Zhu, Yang Yang, Weijia Peng, Qiuhe Chen, Shinghung Mak, Karl Wahkeung Tism, Rongbiao Pi

Abstract readReview
PubMed Publisher
In one paragraph

Review in Mini reviews in medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yuan LiuSchool of Medicine, Shenzhen Campus of Sun Yat-sen University, Shenzhen, 518107, China.ORCID 0009-0000-9849-5854
Zhixian ZhangSchool of Medicine, Shenzhen Campus of Sun Yat-sen University, Shenzhen, 518107, China.ORCID 0009-0007-3852-575X
Zeyu ZhuSchool of Medicine, Shenzhen Campus of Sun Yat-sen University, Shenzhen, 518107, China.
Yang YangSchool of Medicine, Shenzhen Campus of Sun Yat-sen University, Shenzhen, 518107, China.
Weijia PengSchool of Medicine, Shenzhen Campus of Sun Yat-sen University, Shenzhen, 518107, China.
Qiuhe ChenSchool of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, China.
Shinghung MakDivision of Life Science and Center for Chinese Medicine, The Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong, China.
Karl Wahkeung TismDivision of Life Science and Center for Chinese Medicine, The Hong Kong University of Science and Technology, Clear Water Bay, Hong Kong, China.
Rongbiao PiSchool of Medicine, Shenzhen Campus of Sun Yat-sen University, International Joint Laboratory (SYSU-PolyU HK) of Novel Antidementia Drugs of Guangdong Province, Shenzhen, 518107, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's Disease (AD) is a progressive neurodegenerative disorder that leads to cognitive decline and memory impairment. It is characterized by the accumulation of Amyloid-beta (Aβ) plaques, the abnormal phosphorylation of tau protein forming neurofibrillary tangles, and is often accompanied by neuroinflammation and oxidative stress, which contribute to neuronal loss and brain atrophy. At present, clinical anti-AD drugs are mostly single-target, improving the cognitive ability of AD patients, but failing to effectively slow down the progression of AD. Therefore, research on effective multi-target drugs for AD has become an urgent problem to address. The main derivatives of hydroxycinnamic acid, caffeic acid, and ferulic acid, are widely present in nature and have many pharmacological activities, such as antimicrobial, antioxidant, anti-inflammatory, neuroprotective, anti-Aβ deposition, and so on. The occurrence and development of AD are often accompanied by pathologies, such as oxidative stress, neuroinflammation, and Aβ deposition, suggesting that caffeic acid and ferulic acid can be used in the research on anti-AD drugs. Therefore, in this article, we have summarized the multi-target anti-AD derivatives based on caffeic acid and ferulic acid in recent years, and discussed the new design direction of cinnamic acid derivatives as backbone compounds. It is hoped that this review will provide some useful strategies for anti-AD drugs based on cinnamic acid derivatives.

Indexed as

Alzheimer DiseaseCinnamatesNeuroprotective AgentsAmyloid beta-PeptidesAnimalsCaffeic AcidsCoumaric AcidsDrug DevelopmentHumansOxidative StressAmyloid beta-PeptidesCaffeic AcidsCinnamatescinnamic acidCoumaric Acidsferulic acidNeuroprotective AgentsAlzheimer’s diseasecaffeic acidferulic acidhybridsmulti-target-directed ligandsneurodegenerative disease.

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.